(Q58614520)

English

A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Josep Tabernero Caturla

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Viktor Grünwald

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Harald Singer

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Ramon Salazar

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jose Luis Iglesias

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Esther Casado

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Martin Cullell-Young

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Patrick Schöffski

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jose Baselga

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

7 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

299-305

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9529-9

21 January 2018

The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9529-9

21 January 2018

The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9529-9

21 January 2018

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9529-9

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9529-9

21 January 2018

Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9529-9

21 January 2018

Kahalalide F and ES285: potent anticancer agents from marine molluscs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20820909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9529-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820909%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58614520&oldid=2213876245"